Article

Eye and cornea research made easier by two antibodies

A global biotechnology company focused in inflammation and neurology research, announced the launch of two monoclonal antibodies (Lumican and Keratocan, MD Biosciences).

St. Paul, MN-A global biotechnology company focused in inflammation and neurology research, announced the launch of two monoclonal antibodies (Lumican and Keratocan, MD Biosciences). Both antibodies play a role in the development and maintenance of corneal transparency making them ideal for applications in eye and cornea research.

The antibodies belong to the Small Leucine Rich Proteglycan family. Keratocan originally was found to be a cornea-specific keratan sulphate proteoglycan. Lumican is a proteoglycan expressed in extracellular matrix and connective tissues where it has been reported to contribute to collagen fibrillogenesis, tissue hydration, migration, and proliferation.

Lumican modified with keratan sulphate, constitutes one of the major proteoglycans of the corneal stroma, where it stimulates cell migration on the corneal epithelium and also is believed to play a regulatory role for keratocan.

The Lumican antibody recognizes a protein epitope and is specific for human, bovine, mouse, and porcine tissues. The keratocan antibody recognizes a protein core epitope and is specific for human, bovine, porcine, mouse, and chicken tissues.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
Shehzad Batliwala, DO, aka Dr. Shehz, discussed humanitarian ophthalmology and performing refractive surgery in low-resource, high-risk areas at the ASCRS Foundation Symposium.
(Image credit: Ophthalmology Times) ASCRS 2025: Advancing vitreous care with Inder Paul Singh, MD
(Image credit: Ophthalmology Times) The Residency Report: Study provides new insights into USH2A target end points
Lisa Nijm, MD, says preoperative osmolarity testing can manage patient expectations and improve surgical results at the 2025 ASCRS annual meeting
At the 2025 ASCRS Annual Meeting, Weijie Violet Lin, MD, ABO, shares highlights from a 5-year review of cross-linking complications
Maanasa Indaram, MD, is the medical director of the pediatric ophthalmology and adult strabismus division at University of California San Francisco, and spoke about corneal crosslinking (CXL) at the 2025 ASCRS annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Taylor Strange, DO, assesses early visual outcomes with femto-created arcuate incisions in premium IOL cases
(Image credit: Ophthalmology Times) ASCRS 2025: Neda Shamie, MD, shares her early clinical experience with the Unity VCS system
Patricia Buehler, MD, MPH, founder and CEO of Osheru, talks about the Ziplyft device for noninvasive blepharoplasty at the 2025 American Society of Cataract and Refractive Surgeons (ASCRS) annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Bonnie An Henderson, MD, on leveraging artificial intelligence in cataract refractive surgery
© 2025 MJH Life Sciences

All rights reserved.